Earnings call: Harvard Bioscience faces Q1 challenges, eyes H2 recovery By Investing.com

Harvard Bioscience (NASDAQ: [HBIO](/equities/harvard-bioscienc)) has reported a challenging first quarter for 2024, with a noticeable decline in sales, particularly in the China and Asia Pacific markets, and faced supply chain issues.
Read more...